Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor

Neuroscience

Volumn 204, Issue , 2012, Pages 53-63

  Kerr, D M ^a   Burke, N N ^a   Ford, G K ^a   Connor, T J ^b   Harhen, B ^a   Egan, L J ^a   Finn, D P ^a   Roche, M ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

2 AG; Anandamide; Cytokine; Endocannabinoid; HPA axis

Indexed keywords

ANANDAMIDE; CORTICOSTERONE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; ETHANOLAMINE; FATTY ACID AMIDASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; N OLEOYLETHANOLAMINE; PALMIDROL; SUPPRESSOR OF CYTOKINE SIGNALING;

ACUTE STRESS DISORDER; ANIMAL EXPERIMENT; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOKINE RELEASE; DEGRADATION; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HYPOTHALAMUS; MALE; MEDIATOR; NEUROIMMUNOLOGY; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BENZAMIDES; CARBAMATES; CYTOKINES; ENDOCANNABINOIDS; HYPOTHALAMUS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PHYSIOLOGICAL;

EID: 84857128127     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.09.032     Document Type: Review

References (81)

1. Alhouayek M., Lambert D.M., Delzenne N.M., Cani P.D., Muccioli G.G. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 2011, 25(8):2711-2721.
2. Baker B.J., Akhtar L.N., Benveniste E.N. SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol 2009, 30:392-400.
3. Baker D., Jackson S.J., Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol 2007, 152:649-654.
4. Beishuizen A., Thijs L.G. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003, 9:3-24.
5. Berdyshev E., Boichot E., Corbel M., Germain N., Lagente V. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci 1998, 63:PL125-PL129.
6. Berlato C., Cassatella M.A., Kinjyo I., Gatto L., Yoshimura A., Bazzoni F. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol 2002, 168:6404-6411.
7. Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, Boger DL, Cravatt BF, Lichtman AH (in press) The FAAH inhibitor PF-3845 acts in the nervous system to reverse lipopolysaccharide-induced tactile allodynia in mice. Br J Pharmacol, in press.
8. Borges B.C., Rorato R., Avraham Y., da Silva L.E., Castro M., Vorobiav L., Berry E., Antunes-Rodrigues J., Elias L.L. Leptin resistance and desensitization of hypophagia during prolonged inflammatory challenge. Am J Physiol Endocrinol Metab 2011, 300:E858-E869.
9. Breder C.D., Hazuka C., Ghayur T., Klug C., Huginin M., Yasuda K., Teng M., Saper C.B. Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration. Proc Natl Acad Sci U S A 1994, 91:11393-11397.
10. Caraceni P., Pertosa A.M., Giannone F., Domenicali M., Grattagliano I., Principe A., Mastroleo C., Perrelli M.G., Cutrin J., Trevisani F., Croci T., Bernardi M. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 2009, 58:1135-1143.
11. Centonze D., Finazzi-Agrò A., Bernardi G., Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 2007, 28:180-187.
12. Chang Y.H., Lee S.T., Lin W.W. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 2001, 81:715-723.
13. Comelli F., Giagnoni G., Bettoni I., Colleoni M., Costa B. The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol 2007, 152:787-794.
14. Conti B., Tabarean I., Andrei C., Bartfai T. Cytokines and fever. Front Biosci 2004, 9:1433-1449.
15. Correa F., Docagne F., Mestre L., Clemente D., Hernangómez M., Loría F., Guaza C. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol 2009, 77:86-100.
16. Correa F., Hernangómez M., Mestre L., Loría F., Spagnolo A., Docagne F., Di Marzo V., Guaza C. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 2010, 58:135-147.
17. Cota D. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2008, 20(suppl 1):35-38.
18. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signalling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001, 98:9371-9376.
19. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
20. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
21. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 2009, 29:247-264.
22. De Laurentiis A., Fernandez-Solari J., Mohn C., Burdet B., Zorrilla Zubilete M.A., Rettori V. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. J Neuroimmunol 2010, 221:32-41.
23. Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3:771-784.
24. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 1999, 264:258-267.
25. Di Marzo V., Bisogno T., Sugiura T., Melck D., De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 1998, 331(Pt 1):15-19.
26. Di S., Malcher-Lopes R., Marcheselli V.L., Bazan N.G., Tasker J.G. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005, 146:4292-4301.
27. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 2002, 99:10819-10824.
28. Evanson N.K., Tasker J.G., Hill M.N., Hillard C.J., Herman J.P. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology 2010, 151:4811-4819.
29. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 2003, 41:161-168.
30. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005, 313:352-358.
31. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996, 393:231-235.
32. Fernandez-Solari J., Prestifilippo J.P., Bornstein S.R., McCann S.M., Rettori V. Participation of the endocannabinoid system in the effect of TNF-alpha on hypothalamic release of gonadotropin-releasing hormone. Ann N Y Acad Sci 2006, 1088:238-250.
33. Finn D.P. Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance. Immunobiology 2010, 215:629-646.
34. Frobøse H., Rønn S.G., Heding P.E., Mendoza H., Cohen P., Mandrup-Poulsen T., Billestrup N. Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol 2006, 20:1587-1596.
35. Gorzalka B.B., Hill M.N. Integration of endocannabinoid signaling into the neural network regulating stress-induced activation of the hypothalamic-pituitary-adrenal axis. Curr Top Behav Neurosci 2009, 1:289-306.
36. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990, 87:1932-1936.
37. Hill M.N., McLaughlin R.J., Pan B., Fitzgerald M.L., Roberts C.J., Lee T.T., Karatsoreos I.N., Mackie K., Viau V., Pickel V.M., McEwen B.S., Liu Q.S., Gorzalka B.B., Hillard C.J. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 2011, 31:10506-10515.
38. Hoareau L., Buyse M., Festy F., Ravanan P., Gonthier M.P., Matias I., Petrosino S., Tallet F., d'Hellencourt C.L., Cesari M., Di Marzo V., Roche R. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. Obesity (Silver Spring) 2009, 17:431-438.
39. Hollis J.H., Jonaidi H., Lemus M., Oldfield B.J. The endocannabinoid arachidonylethanolamide attenuates aspects of lipopolysaccharide-induced changes in energy intake, energy expenditure and hypothalamic Fos expression. J Neuroimmunol 2011, 233:127-134.
40. Hollis J.H., Lemus M., Evetts M.J., Oldfield B.J. Central interleukin-10 attenuates lipopolysaccharide-induced changes in food intake, energy expenditure and hypothalamic Fos expression. Neuropharmacology 2010, 58:730-738.
41. Holt S., Comelli F., Costa B., Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 2005, 146:467-476.
42. Hübschle T., Thom E., Watson A., Roth J., Klaus S., Meyerhof W. Leptin-induced nuclear translocation of STAT3 immunoreactivity in hypothalamic nuclei involved in body weight regulation. J Neurosci 2001, 21:2413-2424.
43. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2006, 147:281-288.
44. Karlsen A.E., Heding P.E., Frobøse H., Rønn S.G., Kruhøffer M., Orntoft T.F., Darville M., Eizirik D.L., Pociot F., Nerup J., Mandrup-Poulsen T., Billestrup N. Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1beta-mediated toxicity through inhibition of multiple nuclear factor-kappaB-regulated proapoptotic pathways. Diabetologia 2004, 47:1998-2011.
45. Kathuria S., Gaetani S., Fegley D., Valiño F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003, 9:76-81.
46. Kent S., Rodriguez F., Kelley K.W., Dantzer R. Reduction in food and water intake induced by microinjection of interleukin-1beta in the ventromedial hypothalamus of the rat. Physiol Behav 1994, 56:1031-1036.
47. Konsman J.P., Kelley K., Dantzer R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience 1999, 89:535-548.
48. Kozela E., Pietr M., Juknat A., Rimmerman N., Levy R., Vogel Z. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 2010, 285:1616-1626.
49. Lavon I., Sheinin T., Meilin S., Biton E., Weksler A., Efroni G., Bar-Joseph A., Fink G., Avraham A. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 2003, 64:1334-1341.
50. Ledeboer A., Binnekade R., Brevé J.J., Bol J.G., Tilders F.J., Van Dam A.M. Site-specific modulation of LPS-induced fever and interleukin-1beta expression in rats by interleukin-10. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1762-R1772.
51. Liu J., Batkai S., Pacher P., Harvey-White J., Wagner J.A., Cravatt B.F., Gao B., Kunos G. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 2003, 278:45034-45039.
52. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavón F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009, 5:37-44.
53. Maccarrone M., De Petrocellis L., Bari M., Fezza F., Salvati S., Di Marzo V., Finazzi-Agrò A. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 2001, 393:321-328.
54. Mastronardi C.A., Yu W.H., McCann S. Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system. Neuroimmunomodulation 2001, 9:148-156.
55. McNamee E.N., Ryan K.M., Griffin E.W., González-Reyes R.E., Ryan K.J., Harkin A., Connor T.J. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration. Brain Behav Immun 2010, 24:660-671.
56. Mestre L., Correa F., Arévalo-Martín A., Molina-Holgado E., Valenti M., Ortar G., Di Marzo V., Guaza C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005, 92:1327-1339.
57. Molina-Holgado F., Molina-Holgado E., Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 1998, 433:139-142.
58. Murakami N., Sakata Y., Watanabe T. Central action sites of interleukin-1beta for inducing fever in rabbits. J Physiol 1990, 428:299-312.
59. Nakajima Y., Furuichi Y., Biswas K.K., Hashiguchi T., Kawahara K., Yamaji K., Uchimura T., Izumi Y., Maruyama I. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett 2006, 580:613-619.
60. O'Sullivan J.B., Ryan K.M., Curtin N.M., Harkin A., Connor T.J. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol 2009, 12:687-699.
61. Olango WM, Roche M, Ford GK, Harhen B, Finn DP (in press) The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nocicpetive tone. Br J Pharmacol, in press.
62. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., Myers L., Mora Z., Tagliaferro P., Gardner E., Brusco A., Akinshola B.E., Liu Q.R., Hope B., Iwasaki S., Arinami T., Teasenfitz L., Uhl G.R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006, 1074:514-536.
63. Orgado J.M., Fernández-Ruiz J., Romero J. The endocannabinoid system in neuropathological states. Int Rev Psychiatry 2009, 21:172-180.
64. Ortega-Gutiérrez S., Molina-Holgado E., Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005, 52:163-168.
65. Panikashvili D., Mechoulam R., Beni S.M., Alexandrovich A., Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappaB inhibition. J Cereb Blood Flow Metab 2005, 25:477-484.
66. Panikashvili D., Shein N.A., Mechoulam R., Trembovler V., Kohen R., Alexandrovich A., Shohami E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006, 22:257-264.
67. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004, 145:5431-5438.
68. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS. Drug Res 2006, 12:21-38.
69. Pitossi F., del Rey A., Kabiersch A., Besedovsky H. Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 1997, 48:287-298.
70. Puffenbarger R.A., Boothe A.C., Cabral G.A. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000, 29:58-69.
71. Qin H., Roberts K.L., Niyongere S.A., Cong Y., Elson C.O., Benveniste E.N. Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia. J Immunol 2007, 179:5966-5976.
72. Read M.A., Whitley M.Z., Williams A.J., Collins T. NF-kappaB and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med 1994, 179:503-512.
73. Roche M., Diamond M., Kelly J.P., Finn D.P. In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J Neuroimmunol 2006, 181:57-67.
74. Roche M., Kelly J.P., O'Driscoll M., Finn D.P. Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology 2008, 125:263-271.
75. Sancho R., Calzado M.A., Di Marzo V., Appendino G., Muñoz E. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol Pharmacol 2003, 63:429-438.
76. Steiner M.A., Wotjak C.T. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 2008, 170:397-432.
77. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology 2009, 56(Suppl 1):244-253.
78. Tham C.S., Whitaker J., Luo L., Webb M. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett 2007, 581:2899-2904.
79. Turrin N.P., Gayle D., Ilyin S.E., Flynn M.C., Langhans W., Schwartz G.J., Plata-Salamán C.R. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res Bull 2001, 54:443-453.
80. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998, 12:1035-1044.
81. Walker J.M., Krey J.F., Chu C.J., Huang S.M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 2002, 121:159-172.